Tumour Lysis Syndrome after Splenic Irradiation in a Patient with JAK2 V617F Post-polycythaemia Vera Myelofibrosis

Clinical Oncology

Volumn 22, Issue 10, 2010, Pages 893-

  Jain, S ^a   Harrison, C ^a   McMullin, M F ^a   Houston, R F ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCIUM; CREATININE; HYDROXYUREA; INFUSION FLUID; JANUS KINASE 2; PHOSPHATE; POTASSIUM; PREDNISOLONE; UREA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGED; CASE REPORT; CHRONIC MYELOID LEUKEMIA; HUMAN; IRRADIATION; LETTER; MALE; MYELOFIBROSIS; NAUSEA; PALLIATIVE THERAPY; PANCYTOPENIA; PHLEBOTOMY; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RADIATION DOSE; SPLEEN; SPLEEN SIZE; SPLENOMEGALY; TUMOR LYSIS SYNDROME;

AGED; HUMANS; JANUS KINASE 2; MALE; MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RADIATION INJURIES; SPLENOMEGALY; TUMOR LYSIS SYNDROME;

EID: 78149497051     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.07.002     Document Type: Letter

References (8)

1. Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127:3-11.
2. Jyothirmayi R., Coltart S. An audit of the indications for and techniques of palliative splenic radiotherapy in the UK. Clin Oncol (R Coll Radiol) 2005, 17:192-194.
3. Pui C.H., Jeha S., Irwin D., Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001, 15:1505-1509.
4. Schifter T., Cohen A., Lewinski U.H. Severe tumor lysis syndrome following splenic irradiation. Am J Hematol 1999, 60:75-76.
5. Chen S.W., Hwang W.S., Tsao C.J., Liu H.S., Huang G.C. Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literature. J Clin Pharm Ther 2005, 30:623-625.
6. McMullin M.F., Bareford D., Campbell P., et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005, 130:174-195.
7. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
8. Verstovsek S., Kantarjian H., Pardanani A., Thomas D., Cortes J., Mesa R. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ETMF). Blood 2008, 112:1762.